Results 201 to 210 of about 362,523 (334)

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR‐Mutated Advanced Nonsmall‐Cell Lung Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are indicated for advanced lung adenocarcinoma patients harboring susceptible EGFR mutations. The aim of this retrospective study was to compare the effectiveness of different generations of EGFR TKIs.
Chia‐Yu Kuo, Tien‐Chi Huang, Chih‐Jen Yang, Mei‐Hsuan Lee, Jui‐Ying Lee, Ying‐Ming Tsai, Kuan‐Li Wu, Cheng‐Hao Chuang, Inn‐Wen Chong, Jen‐Yu Hung   +9 more
wiley   +1 more source

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway. [PDF]

Cell Death Dis
Li C, Shi S, Li L, Wang Y, Yao M, Yu C, Yu C, Xie C.   +7 more
europepmc   +1 more source

miR-34a inhibits tumorigenesis of NSCLC via targeting SIRT6.

, 2018
Libo Ruan, Jun Chen, Litao Ruan, Anjun Tan, Ping Wang   +4 more
openalex   +1 more source

10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial [PDF]

N. Girard, Wei Li, A.I. Spira, Jerome A. Feldman, Mei Ting Mak, Maxwell Sauder, F. Bozorgmehr, P-J. Voon, Cheng‐Ta Yang, J. Cundom, Jorge J. Nieva, P. Tomasini, I. Cicin, T. Romero, S. Sheng, J. Bauml, Jorge Simões, P. Mahadevia, Mark Wildgust, B.C. Cho   +19 more
openalex   +1 more source

USP54 Promotes Ferroptosis in Non‐Small Cell Lung Cancer by Mediating FOXA2 Deubiquitination and Enhancing ACSL4 Transcription

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5‐year survival rate of less than 20% and a high risk of recurrence despite advances in treatment. This study aimed to identify new therapeutic targets to increase the effectiveness of NSCLC treatments.
Rui‐Shi Wei, Yong‐Ping Liu, Chun‐Dong Gu, Shi‐Lei Zhao, Li Feng, Jian‐Rong Yu   +5 more
wiley   +1 more source

Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study

Šejla Cerić, Timur Cerić, Emir Sokolović, Jasmina Dalač, Dragana Miletić, Inga Marijanović, Layan Mattar, Amina Aljić, Selma Agić-Bilalagić, Amera Šadija, Miran Hadžiahmetović, S. Beslija   +11 more
openalex   +2 more sources

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances. [PDF]

Cancers (Basel)
Deng F, Ma W, Wei S.
europepmc   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source